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Conclusion
Our results suggest that a more selective 
approach to using MDM2 testing is 
warranted. The majority of the Lipomas 
tested for MDM2 were negative, and of 
those that came back positive, only 4 
resulted in recurrence. While there was a 
difference in recurrence between lipomas 
and ALTs, there was no difference in time 
to recurrence. Treatment of recurrent 
lipomas/ALTs was surgical excision, 
whether or not the tumor was positive for 
MDM2. MDM2 testing is not without 
financial cost, and in this cohort, testing 
provided little to no change to the 
treatment options. Thus, we support the 
recent recommendations in the literature 
to limit testing for MDM2 to recurrent 
lipomas, lipomatous tumors with equivocal 
cytologic atypia, and deep extremity 
tumors larger than 10cm in patients over 
fifty2. 
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Introduction
Lipomas of the extremities are benign 
soft tumors of adipocytic origin. 
Extremity Atypical Lipomatous Tumors or 
Well-Differentiated Liposarcomas 
(ALT/LS-WD) are low-grade tumors of 
adipocytic origin but with a potential of 
local recurrence1. Differentiating 
between lipomas and ALT/LS-WD based 
on imaging can be difficult.  
Differentiation often relies on both 
histological analysis and cytogenetic 
studies. ALTs are characterized by 
amplification of the MDM2 gene (12q13-
15) and thus cytogenetic MDM2 testing 
can be a useful tool to establish a 
diagnosis2. However, the question arises 
whether ubiquitous testing of lipomas 
and ALT’s is necessary and whether this 
knowledge changes the treatment 
algorithm for the patient.
Methods
We evaluated patients diagnosed 
with ALT/LS-WD and Lipoma 
between 2011 and 2020. 
Demographic data, tumor location, 
treatment, and pathology were 
reviewed.
Results
312 patients were identified: 205 lipomas and 
107 ALTs. Overall recurrence was 3.9% of 
patients (n=8) for lipomas and 27.1% of 
patients (n=29) for ALTs. 
In total 50% of the 312-patient cohort (n=156) 
were tested for MDM2: of 205 lipomas, 
44.87% (n=92) and of the 107 ALTs, 59.8% 
(n=64).
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MDM2 Testing Among Lipomatous Tumors
In terms of follow-up, patients from the 
ALT group had a significantly longer 
(p<.01) duration of follow-up, after  
primary surgical excision, than the 
patients in the lipoma group. The mean 
duration of follow-up after primary 
surgical excision for lipomas was 10.4 
months, while mean duration of follow-up 
for ALTs after primary surgical excision 
was 29.6 months. There was no 
significant difference between the follow-
up duration after primary surgical 
excision of lipomas tested for MDM2 and 
lipomas not tested. In addition, there was 
no significant difference in follow-up 
duration after primary surgical excision 
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Gross pathology of Lipomatous 
Tumor3
Of the lipomas tested for MDM2, 15.22% 
(n=14) tested positive, but only 4 of the 
lipomas that tested positive for MDM2 
recurred. Treatment for these 4 recurrent 
lipomas was surgical excision. Of the 4 
recurrent lipomas that were either negative 
or not tested for MDM2, 2 were treated with 
surgical excision, 1 was lost to follow-up, 
and 1 was treated with observation. 
Treatment of the vast majority of patients 
who recurred, 91.89% (n=34), was surgical 
excision.
Objective
Determine the clinical significance of 
testing for MDM2 gene amplification in 
Lipomatous tumors of the extremities.
8/205 lipomas recurred, and the mean 
follow-up was 10.4 months. Time to 
recurrences was between 24 and 96 
months. Of the 8 patients in the lipoma 
group who recurred, 4 were positive for 
MDM2, but only 3 lipoma patients were 
still in follow-up. Mean follow-up for the 
ALTs was 29.6 months, and 29/107 ALT 
patients recurred. The time to 
recurrences was between 12 and 90 
months. 20/29 were in current follow-up 
but only 10 of these were tested and 
positive for MDM2. 
